Impromidine (SK&F 92676) is a very potent and specific agonist for histamine H2 receptors
Durant, G.J.; Duncan, W.A.; Ganellin, C.R.; Parsons, M.E.; Blakemore, R.C.; Rasmussen, A.C.
Nature 276(5686): 403-405
1978
ISSN/ISBN: 0028-0836 PMID: 714166 Document Number: 137994
Document emailed within 1 workday
Related Documents
Molina, E.; Rentz, J.; Hirschowitz, B.I. 1980: Use of impromidine to define specific histamine H-2 effects on gastric secretion, heart rate and blood pressure in conscious dogs Journal of Pharmacology and Experimental Therapeutics 214(3): 483-487Kem, W.R.; Mahnir, V.M.; Papke, R.L.; Lingle, C.J. 1997: Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors Journal of Pharmacology and Experimental Therapeutics 283(3): 979-992
Seifert, R.; Höer, A.; Schwaner, I.; Buschauer, A. 1992: Histamine increases cytosolic Ca2+ in HL-60 promyelocytes predominantly via H2 receptors with an unique agonist/antagonist profile and induces functional differentiation Molecular Pharmacology 42(2): 235-241
Evans, B.E. 1991: Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors Zeitschrift für Gastroenterologie. Verhandlungsband 26: 269-271
Tsai, B.S.; Lefkowitz, R.J. 1979: Agonist-specific effects of guanine nucleotides on alpha-adrenergic receptors in human platelets Molecular Pharmacology 16(1): 61-68
Tsai, B.S.; Lefkowitz, R.J. 1978: Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets Molecular Pharmacology 14(4): 540-548
Cieślewicz, G.; Gondorowicz, K.; Grzelewska-Rzymowska, I.; Rozniecki, J. 1995: Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction Pneumonologia i Alergologia Polska 63(5-6): 281-285
Sajewicz, Z. 1979: Current views on the role of histamine and histamine H2 receptors of parietal cells in the process of gastric secretion Polski Tygodnik Lekarski 34(29): 1171-1173
Nishiwaki, H.; Takeuchi, K.; Okada, M.; Tanaka, H.; Okabe, S. 1989: Stimulation of gastric alkaline secretion by histamine in rats: possible involvement of histamine H2-receptors and endogenous prostaglandins Journal of Pharmacology and Experimental Therapeutics 248(2): 793-798
Wegge, T.; Schwarz, S.; Seitz, G. 2000: An alternative improved synthesis of (-)-norferruginine, a potent nAChR agonist Die Pharmazie 55(10): 779-780
Brennan, M.J.; Cantrill, R.C. 1979: Delta-aminolaevulinic acid is a potent agonist for GABA autoreceptors Nature 280(5722): 514-515
Grund, V.R.; Goldberg, N.D.; Hunninghake, D.B. 1975: Histamine receptors in adipose tissue: involvement of cyclic adenosine monophosphate and the H2-receptor in the lipolytic response to histamine in isolated canine fat cells Journal of Pharmacology and Experimental Therapeutics 195(1): 176-184
Nathanson, J.A.; Hunnicutt, E.J. 1981: N-demethylchlordimeform: a potent partial agonist of octopamine-sensitive adenylate cyclase Molecular Pharmacology 20(1): 68-75
Burris, K.D.; Breeding, M.; Sanders-Bush, E. 1991: (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist Journal of Pharmacology and Experimental Therapeutics 258(3): 891-896
Satoh, M.; Sakai, T.; Sano, I.; Fujikura, K.; Koyama, H.; Ohshima, K.; Itoh, Z.; Omura, S. 1994: EM574, an erythromycin derivative, is a potent motilin receptor agonist in human gastric antrum Journal of Pharmacology and Experimental Therapeutics 271(1): 574-579
Uhl, D. 1989: Histamine, histamine receptors and antihistaminics Medizinische Monatsschrift für Pharmazeuten 12(5): 138-140
Koek, W.; Patoiseau, J.F.; Assié, M.B.; Cosi, C.; Kleven, M.S.; Dupont-Passelaigue, E.; Carilla-Durand, E.; Palmier, C.; Valentin, J.P.; John, G.; Pauwels, P.J.; Tarayre, J.P.; Colpaert, F.C. 1998: F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential Journal of Pharmacology and Experimental Therapeutics 287(1): 266-283
Ligneau, X.; Lin, J.; Vanni-Mercier, G.; Jouvet, M.; Muir, J.L.; Ganellin, C.R.; Stark, H.; Elz, S.; Schunack, W.; Schwartz, J. 1998: Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist Journal of Pharmacology and Experimental Therapeutics 287(2): 658-666
Katz, L.B.; Scott, C.K.; Shriver, D.A. 1986: Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine Journal of Pharmacology and Experimental Therapeutics 238(2): 587-593
Rodríguez de Fonseca, F.; Rubio, P.; Menzaghi, F.; Merlo-Pich, E.; Rivier, J.; Koob, G.F.; Navarro, M. 1996: Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats Journal of Pharmacology and Experimental Therapeutics 276(1): 56-64